Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trialThomas L Holland, Robert C. Hyzy, Nicole Engen et al.|The Lancet Respiratory Medicine|2022Cited by 127
A Randomized Trial of Mesenchymal Stromal Cells for Moderate to Severe Acute Respiratory Distress Syndrome from COVID-19Michael E. Bowdish, Annetine C. Gelijns, Christina E. Barkauskas et al.|American Journal of Respiratory and Critical Care Medicine|2022Cited by 71